| Lynn C Andrews, CRNA | |
|
6000 W Spring Creek Pkwy Ste 150, Plano, TX 75024-4111 | |
| (468) 559-5880 | |
| (888) 514-7033 |
| Full Name | Lynn C Andrews |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 20 Years |
| Location | 6000 W Spring Creek Pkwy Ste 150, Plano, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003802216 | NPI | - | NPPES |
| 200078690 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 28158485A (Indiana) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | AP137189 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White All Saints Medical Center Fort Worth | Fort worth, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Anesthesia Iii Pa | 0042630501 | 335 |
| Northstar Anesthesia Pa | 7315907128 | 290 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Northstar Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Champion Anesthesia Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649676024 PECOS PAC ID: 7113231358 Enrollment ID: O20150803000277 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Texas Anesthesia Partners, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144673468 PECOS PAC ID: 3870879828 Enrollment ID: O20170406000406 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Northstar Anesthesia Ii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477066405 PECOS PAC ID: 2365701737 Enrollment ID: O20180110000102 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Orthomed Staffing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225514276 PECOS PAC ID: 9638429178 Enrollment ID: O20180905000794 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Sp Pain Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679078075 PECOS PAC ID: 8022360437 Enrollment ID: O20181012002465 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Northstar Anesthesia Iii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356968952 PECOS PAC ID: 0042630501 Enrollment ID: O20201022000080 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Entity Name | Synapse Anesthesia Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710652789 PECOS PAC ID: 6507262607 Enrollment ID: O20210914002755 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lynn C Andrews, CRNA Po Box 674293, Dallas, TX 75267-4293 Ph: (469) 559-5880 | Lynn C Andrews, CRNA 6000 W Spring Creek Pkwy Ste 150, Plano, TX 75024-4111 Ph: (468) 559-5880 |
News Archive
A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.
PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).
News outlets across the country are reporting that states are planning to trim Medicaid rolls and benefits. Some are especially focusing on nursing home costs.
› Verified 6 days ago
Taylor Nicole Mcfarlin, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 6200 W Parker Rd, Plano, TX 75093 Phone: 972-981-8000 | |
Amanda Frampton Watts, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 6712 Hornbeam Ct, Plano, TX 75023 Phone: 903-752-3060 | |
Mr. Robert L. Roberts, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 3901 W 15th St, Plano, TX 75075 Phone: 972-519-1115 Fax: 972-519-1456 | |
Byron Razon, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 6200 W Parker Rd, Plano, TX 75093 Phone: 469-644-0830 | |
John David Caley, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 6009 W Parker Rd, Suite 149-245, Plano, TX 75093 Phone: 214-244-8796 Fax: 972-781-1461 | |
Kyle M Shadle, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1708 Coit Rd, Suite 220a, Plano, TX 75075 Phone: 972-596-6400 Fax: 972-867-4766 |